Dr Alex Alderton

Head of Cellular Operations

Alumni

This person is a member of Sanger Institute Alumni.

Alex was Head of Cellular Operations at the Sanger Institute until 2021 when she left to join AstraZeneca.

Alex was the Head of Cellular Operations at the Wellcome Sanger Institute. In this role she led a team of 75 scientists covering a broad range of scientific areas including flow cytometry, CRISPR genome editing, stem cells, screening,  imaging and organoid derivation. Collectively, the team provided cell biology expertise to help deliver some of the institutes largest and most ambitious projects.

Alex has a background in cell and molecular biology, in particular the development of cell lines and assays for large scale or high throughput science. She completed a Post doc on prion-based neurological disorders at the University of Bath in 2006 before joining Pfizer to work in cell line and assay development for a variety of early stage drug discovery projects. In 2012, Alex move to the Sanger to take up a senior role in the newly formed Cellular Generation and Phenotyping (CGaP) core facility, where she went onto become the facility head in 2015. In 2017, Alex became Head of Cellular Operations.

My timeline

• Head of Cellular Operations at the Sanger Institute

• Head of Cellular Generation and Phenotyping at the Sanger Institute

• Senior Scientific Manager at the Sanger Institute

• Principal Scientist, Research Enabling Group at Pfizer

• Senior Scientist, Primary Pharmacology Group at Pfizer

• Screening Scientist, Primary Pharmacology Group at Pfizer

• Post Doc at University of Bath

• PhD in Molecular Biology, University of Kent